Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
Rifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associated tuberculosis because of drug-drug interactions. Rifabutin has been proposed as an alternative rifamycin, but there is concern that the current recommended dose is suboptimal. The principal aim of th...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3898920?pdf=render |
id |
doaj-b89f5358bb8b4ee09eef9e15269e454d |
---|---|
record_format |
Article |
spelling |
doaj-b89f5358bb8b4ee09eef9e15269e454d2020-11-25T01:49:53ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8486610.1371/journal.pone.0084866Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.Nguyen Thi Ngoc LanNguyen Thi Nguyet ThuAurélie Barrail-TranNguyen Hong DucNguyen Ngoc LanDidier LaureillardTruong Thi Xuan LienLaurence BorandCatherine QuilletCatherine ConnollyDominique LagardeAlexander PymChristian LienhardtNguyen Huy DungAnne-Marie TaburetAnthony D HarriesRifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associated tuberculosis because of drug-drug interactions. Rifabutin has been proposed as an alternative rifamycin, but there is concern that the current recommended dose is suboptimal. The principal aim of this study was to compare bioavailability of two doses of rifabutin (150 mg three times per week and 150 mg daily) in patients with HIV-associated tuberculosis who initiated lopinavir/ritonavir-based antiretroviral therapy in Vietnam. Concentrations of lopinavir/ritonavir were also measured.This was a randomized, open-label, multi-dose, two-arm, cross-over trial, conducted in Vietnamese adults with HIV-associated tuberculosis in Ho Chi Minh City (Clinical trial registry number NCT00651066). Rifabutin pharmacokinetics were evaluated before and after the introduction of lopinavir/ritonavir -based antiretroviral therapy using patient randomization lists. Serial rifabutin and 25-O-desacetyl rifabutin concentrations were measured during a dose interval after 2 weeks of rifabutin 300 mg daily, after 3 weeks of rifabutin 150 mg daily with lopinavir/ritonavir and after 3 weeks of rifabutin 150 mg three times per week with lopinavir/ritonavir.Sixteen and seventeen patients were respectively randomized to the two arms, and pharmacokinetic analysis carried out in 12 and 13 respectively. Rifabutin 150 mg daily with lopinavir/ritonavir was associated with a 32% mean increase in rifabutin average steady state concentration compared with rifabutin 300 mg alone. In contrast, the rifabutin average steady state concentration decreased by 44% when rifabutin was given at 150 mg three times per week with lopinavir/ritonavir. With both dosing regimens, 2 - 5 fold increases of the 25-O-desacetyl- rifabutin metabolite were observed when rifabutin was given with lopinavir/ritonavir compared with rifabutin alone. The different doses of rifabutin had no significant effect on lopinavir/ritonavir plasma concentrations.Based on these findings, rifabutin 150 mg daily may be preferred when co-administered with lopinavir/ritonavir in patients with HIV-associated tuberculosis.ClinicalTrials.gov NCT00651066.http://europepmc.org/articles/PMC3898920?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nguyen Thi Ngoc Lan Nguyen Thi Nguyet Thu Aurélie Barrail-Tran Nguyen Hong Duc Nguyen Ngoc Lan Didier Laureillard Truong Thi Xuan Lien Laurence Borand Catherine Quillet Catherine Connolly Dominique Lagarde Alexander Pym Christian Lienhardt Nguyen Huy Dung Anne-Marie Taburet Anthony D Harries |
spellingShingle |
Nguyen Thi Ngoc Lan Nguyen Thi Nguyet Thu Aurélie Barrail-Tran Nguyen Hong Duc Nguyen Ngoc Lan Didier Laureillard Truong Thi Xuan Lien Laurence Borand Catherine Quillet Catherine Connolly Dominique Lagarde Alexander Pym Christian Lienhardt Nguyen Huy Dung Anne-Marie Taburet Anthony D Harries Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS ONE |
author_facet |
Nguyen Thi Ngoc Lan Nguyen Thi Nguyet Thu Aurélie Barrail-Tran Nguyen Hong Duc Nguyen Ngoc Lan Didier Laureillard Truong Thi Xuan Lien Laurence Borand Catherine Quillet Catherine Connolly Dominique Lagarde Alexander Pym Christian Lienhardt Nguyen Huy Dung Anne-Marie Taburet Anthony D Harries |
author_sort |
Nguyen Thi Ngoc Lan |
title |
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. |
title_short |
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. |
title_full |
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. |
title_fullStr |
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. |
title_full_unstemmed |
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. |
title_sort |
randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with hiv-associated tuberculosis in vietnam. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
Rifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associated tuberculosis because of drug-drug interactions. Rifabutin has been proposed as an alternative rifamycin, but there is concern that the current recommended dose is suboptimal. The principal aim of this study was to compare bioavailability of two doses of rifabutin (150 mg three times per week and 150 mg daily) in patients with HIV-associated tuberculosis who initiated lopinavir/ritonavir-based antiretroviral therapy in Vietnam. Concentrations of lopinavir/ritonavir were also measured.This was a randomized, open-label, multi-dose, two-arm, cross-over trial, conducted in Vietnamese adults with HIV-associated tuberculosis in Ho Chi Minh City (Clinical trial registry number NCT00651066). Rifabutin pharmacokinetics were evaluated before and after the introduction of lopinavir/ritonavir -based antiretroviral therapy using patient randomization lists. Serial rifabutin and 25-O-desacetyl rifabutin concentrations were measured during a dose interval after 2 weeks of rifabutin 300 mg daily, after 3 weeks of rifabutin 150 mg daily with lopinavir/ritonavir and after 3 weeks of rifabutin 150 mg three times per week with lopinavir/ritonavir.Sixteen and seventeen patients were respectively randomized to the two arms, and pharmacokinetic analysis carried out in 12 and 13 respectively. Rifabutin 150 mg daily with lopinavir/ritonavir was associated with a 32% mean increase in rifabutin average steady state concentration compared with rifabutin 300 mg alone. In contrast, the rifabutin average steady state concentration decreased by 44% when rifabutin was given at 150 mg three times per week with lopinavir/ritonavir. With both dosing regimens, 2 - 5 fold increases of the 25-O-desacetyl- rifabutin metabolite were observed when rifabutin was given with lopinavir/ritonavir compared with rifabutin alone. The different doses of rifabutin had no significant effect on lopinavir/ritonavir plasma concentrations.Based on these findings, rifabutin 150 mg daily may be preferred when co-administered with lopinavir/ritonavir in patients with HIV-associated tuberculosis.ClinicalTrials.gov NCT00651066. |
url |
http://europepmc.org/articles/PMC3898920?pdf=render |
work_keys_str_mv |
AT nguyenthingoclan randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT nguyenthinguyetthu randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT aureliebarrailtran randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT nguyenhongduc randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT nguyenngoclan randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT didierlaureillard randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT truongthixuanlien randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT laurenceborand randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT catherinequillet randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT catherineconnolly randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT dominiquelagarde randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT alexanderpym randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT christianlienhardt randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT nguyenhuydung randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT annemarietaburet randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam AT anthonydharries randomisedpharmacokinetictrialofrifabutinwithlopinavirritonavirantiretroviraltherapyinpatientswithhivassociatedtuberculosisinvietnam |
_version_ |
1725004217939132416 |